Mark Strobeck - 01 Oct 2025 Form 4 Insider Report for ROCKWELL MEDICAL, INC. (RMTI)

Reporting relationship: President and CEO, Director
Issuer ticker: RMTI
Reported as of: 01 Oct 2025
Net transaction value: -$8,242
SEC form: 4
Accepted by SEC: 01 Oct 2025, 16:22:06 UTC
Prior SEC filing: 03 Jul 2025
Next SEC filing: 16 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Megan Timmins, Attorney-in-fact for Mark Strobeck

Key filing fact

Mark Strobeck filed Form 4 for ROCKWELL MEDICAL, INC. (RMTI) on 01 Oct 2025.

Key facts

This page summarizes Mark Strobeck's Form 4 filing for ROCKWELL MEDICAL, INC. (RMTI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Oct 2025, 16:22.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: -$8,242.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001599219 Primary reporting owner

Strobeck Mark

Relationship: President and CEO, Director
Address: 30142 WIXOM ROAD, WIXOM
Signature: /s/ Megan Timmins, Attorney-in-fact for Mark Strobeck
Signature date: 01 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RMTI transaction

Common Stock

Sale

Transaction value: $8,242
Shares: -6,926
Change %: -2.1%
Price: $1.19
Shares after: 330,826
Date: 01 Oct 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. The price reported above reflects the sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.